Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Their second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/25/24 | $132,500,000 | Series C |
abrdn Ally Bridge Group Avidity Partners AyurMaya  Eckuity Fidelity Management & Research Company Invus Longitude Capital Omega Funds Perceptive Advisors Piper Heartland Healthcare Capital Silver Arch Bio Symbiosis T. Rowe Price Associates Velosity Capital Woodline Partners | undisclosed |
